Inga Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inga Hansen has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Nina Booken
17 shared publicationsStefan W. Schneider
15 shared publicationsFinn Abeck
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf , Hamburg
13 shared publications- Christoffer Gebhardt
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf , Hamburg
9 shared publications - Julian Kött
Department of Dermatology and Venereology University Medical Center Hamburg‐Eppendorf Hamburg Germany
9 shared publications Isabel Heidrich
Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf , Hamburg
7 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Quantitative Clonality Analysis of T-cell Receptor Rearrangement in Mogamulizumab-associated Rash
- 18 November 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessQuantitative Clonality Analysis of T-cell Receptor Rearrangement in Mogamulizumab-associated Rash
- Open Access
- 17 November 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review
Summary: Mogamulizumab is a monoclonal antibody targeting CC‐chemokine receptor‐4 that is approved as a second‐line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion‐related reactions and mogamulizumab‐associated rash. Conversely, solid organ involvement in immune‐related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune‐mediated adverse events involving solid organs are potentially life‐threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non‐infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune‐mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.
- 17 November 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Open AccessImmune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review
Summary: Mogamulizumab is a monoclonal antibody targeting CC‐chemokine receptor‐4 that is approved as a second‐line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion‐related reactions and mogamulizumab‐associated rash. Conversely, solid organ involvement in immune‐related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune‐mediated adverse events involving solid organs are potentially life‐threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non‐infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune‐mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.
- 1 September 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Topology and the impact on quality of life of cutaneous T-cell lymphomas: a cross-sectional study of 153 patients
Background: Cutaneous T-cell lymphomas (CTCLs) comprise a clinically, histologically and molecularly heterogeneous group of subtypes. They fulfil aspects of both chronic and malignant skin conditions and may thus affect health-related quality of life (HRQL) in various ways. To date, there is little information known about the topology of patients with CTCL in routine care. Objectives: To characterize the frequency and distribution of body sites affected by CTCLs in routine care and to analyse the impact on HRQL. Methods: Cross-sectional survey study, as part of the routine care at a university medical centre. Topical distribution was identified with a detailed grid scheme filled in by the patient, and the affected body surface area (BSA) was recorded by the physician. Skindex-29 measured HRQL. Results: In total, 153 patients with CTCL were included, with a mean age of 59.5 (SD 16.5) years and the majority were male patients (61.4%, 94/153). The mean number of grids marked was 129.2 (SD 263.8), corresponding to 12.7% of the BSA, and the most frequently affected body areas were thighs, back and lower legs. Skindex-29 revealed that HRQL in patients with CTCL is impaired on a mild level, with a mean of 27.5 (SD 21.3). Patients with involvement of the visible or genital areas showed a significantly poorer HRQL. Overall, 70.0% (107/153) of patients reported relevant pruritus (numeric rating scale ≥ 3), which was strongly associated with worse HRQL, independent of localization. Linear regression analysis revealed a significant correlation between an increased impairment of HRQL and a higher BSA, a manifestation in visible areas, and a higher itching intensity. Conclusions: This analysis provides data on the distribution of CTCLs in routine care. Our study highlights the importance of specific areas, such as visible body areas or the genital area, as determinants for the reduction of HRQL. This knowledge can help to improve patient-centred healthcare in CTCL.
- 1 September 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Topology and the impact on quality of life of cutaneous T-cell lymphomas: a cross-sectional study of 153 patients
Background: Cutaneous T-cell lymphomas (CTCLs) comprise a clinically, histologically and molecularly heterogeneous group of subtypes. They fulfil aspects of both chronic and malignant skin conditions and may thus affect health-related quality of life (HRQL) in various ways. To date, there is little information known about the topology of patients with CTCL in routine care. Objectives: To characterize the frequency and distribution of body sites affected by CTCLs in routine care and to analyse the impact on HRQL. Methods: Cross-sectional survey study, as part of the routine care at a university medical centre. Topical distribution was identified with a detailed grid scheme filled in by the patient, and the affected body surface area (BSA) was recorded by the physician. Skindex-29 measured HRQL. Results: In total, 153 patients with CTCL were included, with a mean age of 59.5 (SD 16.5) years and the majority were male patients (61.4%, 94/153). The mean number of grids marked was 129.2 (SD 263.8), corresponding to 12.7% of the BSA, and the most frequently affected body areas were thighs, back and lower legs. Skindex-29 revealed that HRQL in patients with CTCL is impaired on a mild level, with a mean of 27.5 (SD 21.3). Patients with involvement of the visible or genital areas showed a significantly poorer HRQL. Overall, 70.0% (107/153) of patients reported relevant pruritus (numeric rating scale ≥ 3), which was strongly associated with worse HRQL, independent of localization. Linear regression analysis revealed a significant correlation between an increased impairment of HRQL and a higher BSA, a manifestation in visible areas, and a higher itching intensity. Conclusions: This analysis provides data on the distribution of CTCLs in routine care. Our study highlights the importance of specific areas, such as visible body areas or the genital area, as determinants for the reduction of HRQL. This knowledge can help to improve patient-centred healthcare in CTCL.
- Open Access
- 4 August 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1123-1125
Erfolgreiche multimodale Therapie der CD30‐positiven follikulotropen Mycosis fungoides
- 4 August 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8) , 1123-1125
Open AccessErfolgreiche multimodale Therapie der CD30‐positiven follikulotropen Mycosis fungoides
- Open Access
- 11 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Current state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study
Summary: Background: Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods: Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German university hospital. The physician questionnaire recorded the skin‐related burden of disease using the mSWAT and data on disease course, while the patient questionnaire recorded socio‐demographic and clinical parameters, patient satisfaction, and health‐related quality of life using the Skindex‐29. Results: 121 patients (median age 63 years, 66.9 % male) with mycosis fungoides (95.0 %) and Sézary syndrome (5.0 %) were included. 30.0 % of the working patients reported sick leave due to CTCL and 51.7 % had already been hospitalized at least once for this indication. The Skindex‐29 revealed an impairment in quality of life in 52.9 % of patients. Patients with higher disease stages (IIB–IVB according to EORTC/ISCL), lack of response to therapy, and an mSWAT ≥ 30 showed a significantly higher impairment in quality of life. A median of 4 follow‐up appointments were attended annually, with 63.6 % of patients being treated exclusively at the university hospital. Conclusions: This study is the first to analyze the state of medical care of patients with mycosis fungoides and Sézary syndrome using primary data from routine care at a German university hospital and reveals a high burden of disease as well as a high need for care.
- 11 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Open AccessCurrent state of medical care for patients with mycosis fungoides and Sézary syndrome at a German university hospital – a cross‐sectional study
Summary: Background: Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods: Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German university hospital. The physician questionnaire recorded the skin‐related burden of disease using the mSWAT and data on disease course, while the patient questionnaire recorded socio‐demographic and clinical parameters, patient satisfaction, and health‐related quality of life using the Skindex‐29. Results: 121 patients (median age 63 years, 66.9 % male) with mycosis fungoides (95.0 %) and Sézary syndrome (5.0 %) were included. 30.0 % of the working patients reported sick leave due to CTCL and 51.7 % had already been hospitalized at least once for this indication. The Skindex‐29 revealed an impairment in quality of life in 52.9 % of patients. Patients with higher disease stages (IIB–IVB according to EORTC/ISCL), lack of response to therapy, and an mSWAT ≥ 30 showed a significantly higher impairment in quality of life. A median of 4 follow‐up appointments were attended annually, with 63.6 % of patients being treated exclusively at the university hospital. Conclusions: This study is the first to analyze the state of medical care of patients with mycosis fungoides and Sézary syndrome using primary data from routine care at a German university hospital and reveals a high burden of disease as well as a high need for care.
- 11 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Triple therapy for calciphylaxis: A retrospective analysis of sodium thiosulfate, iloprost, and anticoagulation
Summary: Background: Calciphylaxis is a severe condition with no established therapy, characterized by painful skin ulcerations and necrosis resulting from occlusion of small blood vessels. Given the high mortality rate, effective treatment strategies are urgently needed. We hypothesize that a combination of sodium thiosulphate with the prostaglandin analog iloprost and a low‐molecular‐weight heparin may be a beneficial treatment option for calciphylaxis. Patients and methods: In a retrospective data analysis, 19 patients with calciphylaxis were included who were treated in our clinic between 2019 and 2023. Demographic factors, clinical symptoms, comorbidities, laboratory results, histology, and treatment‐related factors were collected. Results: 68.4% were female and mean age was 67.8 years. In 63% of cases, a combination therapy consisting of sodium thiosulfate, iloprost and anticoagulation was used. In a cohort of 12 patients who underwent at least 2 treatment cycles complete healing occurred in 75.0% of cases and partial improvement in 25.0%. The median time to healing was 3.0 treatment cycles. The median duration until complete pain relief was 2.5 treatment cycles. Conclusions: In our cohort, a combination therapy consisting of sodium thiosulfate, iloprost, and anticoagulation was associated with favorable treatment response, good tolerability, improved wound healing, and pain relief.
- 11 June 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Triple therapy for calciphylaxis: A retrospective analysis of sodium thiosulfate, iloprost, and anticoagulation
Summary: Background: Calciphylaxis is a severe condition with no established therapy, characterized by painful skin ulcerations and necrosis resulting from occlusion of small blood vessels. Given the high mortality rate, effective treatment strategies are urgently needed. We hypothesize that a combination of sodium thiosulphate with the prostaglandin analog iloprost and a low‐molecular‐weight heparin may be a beneficial treatment option for calciphylaxis. Patients and methods: In a retrospective data analysis, 19 patients with calciphylaxis were included who were treated in our clinic between 2019 and 2023. Demographic factors, clinical symptoms, comorbidities, laboratory results, histology, and treatment‐related factors were collected. Results: 68.4% were female and mean age was 67.8 years. In 63% of cases, a combination therapy consisting of sodium thiosulfate, iloprost and anticoagulation was used. In a cohort of 12 patients who underwent at least 2 treatment cycles complete healing occurred in 75.0% of cases and partial improvement in 25.0%. The median time to healing was 3.0 treatment cycles. The median duration until complete pain relief was 2.5 treatment cycles. Conclusions: In our cohort, a combination therapy consisting of sodium thiosulfate, iloprost, and anticoagulation was associated with favorable treatment response, good tolerability, improved wound healing, and pain relief.
- Open Access
- 8 May 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
- 8 May 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Open AccessDupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid
- Open Access
- 6 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8)
Successful Multimodal Therapeutic Approach for CD30‐positive Folliculotropic Mycosis Fungoides
- 6 March 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (8)
Open AccessSuccessful Multimodal Therapeutic Approach for CD30‐positive Folliculotropic Mycosis Fungoides
- Open Access
- 19 December 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 8, e72704
Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review
This narrative review examines the advantages and disadvantages of direct-to-consumer teledermatology for the treatment of male androgenetic alopecia, finding that this treatment modality improves access to care, ensures high adherence rates, and enhances patient satisfaction, while raising concerns about increased drug costs.
- 19 December 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 8, e72704
Open AccessDirect-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review
This narrative review examines the advantages and disadvantages of direct-to-consumer teledermatology for the treatment of male androgenetic alopecia, finding that this treatment modality improves access to care, ensures high adherence rates, and enhances patient satisfaction, while raising concerns about increased drug costs.
- Open Access
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1424-1429
Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen peripheren T‐Zell‐Lymphomen – eine retrospektive Analyse
Zusammenfassung: Hintergrund: Kutane periphere T‐Zell‐Lymphome (PTCL) sind selten und zeigen einen aggressiven Verlauf mit limitiertem Therapieansprechen. Die Wirksamkeit von Brentuximab‐Vedotin bei kutanen PTCL wurde bisher nicht systematisch untersucht. Patienten und Methodik: In dieser retrospektiven Datenanalyse evaluierten wir die Therapie mit Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen CD30‐positiven PTCL (n = 9). Ergebnisse: Insgesamt zeigten sich gutes Ansprechen und akzeptable Verträglichkeit der Therapie. Ein Patient erzielte eine nahezu komplette Remission, bei fünf Patienten wurde eine partielle Remission und bei zwei Patienten ein gemischtes Ansprechen als bestes Ansprechen ( best overall response , BOR) beobachtet. Im Median vergingen 31,5 Tage (Interquartilabstand 12–53) bis zum Therapieansprechen. Die mediane Ansprechdauer war mit 4,3 Monaten kurz; das mediane Gesamtüberleben seit Einleitung der Brentuximab‐Vedotin‐Therapie betrug 15,2 Monate. Vier von neun Patienten verstarben an ihrer fortgeschrittenen Lymphomerkrankung, ein Patient verstarb aus anderer Ursache. Schlussfolgerungen: Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie ist bei Patienten mit kutanem peripheren T‐Zell‐Lymphom eine rasch wirksame und verträgliche Therapieoption bei allerdings nur kurzer Ansprechdauer.
- 14 November 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (11) , 1424-1429
Open AccessBrentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen peripheren T‐Zell‐Lymphomen – eine retrospektive Analyse
Zusammenfassung: Hintergrund: Kutane periphere T‐Zell‐Lymphome (PTCL) sind selten und zeigen einen aggressiven Verlauf mit limitiertem Therapieansprechen. Die Wirksamkeit von Brentuximab‐Vedotin bei kutanen PTCL wurde bisher nicht systematisch untersucht. Patienten und Methodik: In dieser retrospektiven Datenanalyse evaluierten wir die Therapie mit Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen CD30‐positiven PTCL (n = 9). Ergebnisse: Insgesamt zeigten sich gutes Ansprechen und akzeptable Verträglichkeit der Therapie. Ein Patient erzielte eine nahezu komplette Remission, bei fünf Patienten wurde eine partielle Remission und bei zwei Patienten ein gemischtes Ansprechen als bestes Ansprechen ( best overall response , BOR) beobachtet. Im Median vergingen 31,5 Tage (Interquartilabstand 12–53) bis zum Therapieansprechen. Die mediane Ansprechdauer war mit 4,3 Monaten kurz; das mediane Gesamtüberleben seit Einleitung der Brentuximab‐Vedotin‐Therapie betrug 15,2 Monate. Vier von neun Patienten verstarben an ihrer fortgeschrittenen Lymphomerkrankung, ein Patient verstarb aus anderer Ursache. Schlussfolgerungen: Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie ist bei Patienten mit kutanem peripheren T‐Zell‐Lymphom eine rasch wirksame und verträgliche Therapieoption bei allerdings nur kurzer Ansprechdauer.